Changes In Hypertension Control Research Articles

P203 IMPACT OF IMPLEMENTING A COMMUNITY CARE STRATEGY TO REDUCE THE RISK OF CARDIOVASCULAR DISEASE IN SANTANDER, COLOMBIA: PRELIMINARY RESULTS OF THE RE-HOPE STUDY

Background: Hypertension is the main risk factor of cardiovascular disease (CVD), affecting 1.28 billion adults and resulting in 1.16 million deaths. In Colombia, hypertension affected 7.8 million adults in 2019. Different sociocultural and health system-related barriers may interfere with hypertension management. Our aim was to determine the preliminary impact of this community-based strategy on the changes in hypertension control in Colombia. Methods The Re-Hope study is a community-based strategy to reduce CVD risk in 13 municipalities of Santander, Colombia. Nursing assistants referred patients to the cardiovascular risk program (CVRP), facilitated medical appointments, and provided health counseling. A longitudinal analysis was conducted on data from the first three follow-up visits. Included were adults >18 years with hypertension not enrolled in the CVRP. Standardized questionnaires gathered sociodemographic, medication, and lifestyle data. Anthropometric and blood pressure measurements were taken. Hypertension was defined as systolic BP >140 mmHg, diastolic BP >90 mmHg, self-reported hypertension, or antihypertensive medication use. Pharmacological adherence was assessed with the Morisky 4-item scale. Tobacco and alcohol use were categorized as never or current consumers. Blood pressure changes were evaluated with a paired t-test, and categorical variable changes with McNemar and Stuart-Maxwell tests. Analysis was done using Stata software. Results A total of 2,585 participants were included. The mean age was 65.1 years (SD 11.9) and 64.3% were women. After 6 months of follow-up, the mean systolic and diastolic blood pressure reduced 17.03 mmHg (SD 17.95) and 7.04 mmHg (SD 11.22), respectively. Hypertension control increased on 11.7%. Antihypertensive combination therapy increased by 4.4% for dual therapy and 4.6% for triple therapy. The low pharmacological adherence was reduced by 3.35%. Conclusions The implementation of a community-based care strategy in Santander at the first three visits achieved a relevant reduction of hypertension values and greater use of combined antihypertensive therapy. Continuation of the study is required to identify the total results.

Heart on hypertension: Improving hypertension control in the FQHC setting through a group visit program

IntroductionMany solutions for increasing hypertension control rates have been proposed yet the social determinants of health create health disparities within the populations served by Federally Qualified Health Centers (FQHC) that can complicate reaching these goals. This study observes impact of a group visit program on hypertension control within the patient population served by an FQHC. MethodsRetrospective review and analysis of blood pressure data was performed for patients enrolled in the first 4 cohorts of the Heart on Hypertension Group Visit Program at the end of the program as well as 3 months, 6 months, and 12 months after the program ended. Results and discussionTwenty-two patients participated in the program. Seventeen patients achieved the goal with a statistically significant mean change in blood pressure at p > 0.001. Patients who completed the program had a statistically significant mean change in blood pressure at p > 0.001 and those who discontinued prior to completing the program had a statistically significant mean change in blood pressure at p = 0.001 systolic and p = 0.002 diastolic. Changes in patient blood pressure were sustained for 3-months (78%), 6-months (83%), and 12-months (83%). ImplicationsPatients in the Heart on Hypertension program were successful in making significant changes in hypertension control in the FQHC setting. This method was useful in improving hypertension control metrics for patients facing increased influences by the Social Determinants of Health.

Is Home Blood Pressure Monitoring Effective at Controlling Hypertension in African American Patients? A Clin-IQ.

African Americans are disproportionately affected by hypertension, a modifiable contributor to multiple chronic diseases and premature death. Primary care physicians play an important role in hypertension control. Home blood pressure monitoring (HBPM) is an evidence-based method for confirming diagnosis and monitoring hypertension over time. Some studies have found that HBPM may lead to clinically relevant reductions in blood pressure when combined with additional interventions, but few studies have focused specifically on African American populations. Evidence of effectiveness could increase clinical recommendation of HBPM. This clinical inquiry examined whether HBPM improves blood pressure control in African Americans with uncontrolled hypertension. Reviewed studies included 4 randomized controlled trials and 2 comparative research studies. Because these studies often were coupled with various co-interventions, ascertaining the independent effects of HBPM was difficult. When examining reviews of HBPM without a co-intervention and conducted independent of race, HBPM alone was insufficient to achieve long-term changes in hypertension control. More research focused on African Americans, with use of control groups, is needed to determine the true role for HBPM in controlling hypertension in this at-risk patient population.

Association Between a Population Health Intervention and Hypertension Control.

As part of the Centers for Medicare and Medicaid Innovation Practice Transformation Network, an integrated healthcare system implemented a multimodal, population health-based hypertension clinical pathway program (HCPP) focused on hypertension management. To determine whether the HCPP was associated with changes in hypertension control or process-of-care measures and whether associations varied for sites serving higher versus lower proportions of historically underserved patients. An integrated academic health system encompassing 5 clinic networks and 85 primary and specialty care sites. The HCPP was implemented at some sites (adopters) but not others (non-adopters) and had four components: (1) stakeholder engagement; (2) clinical staff retraining; (3) electronic health record-based prompts; and (4) performance monitoring and feedback. Program goals were to encourage clinical teams to increase the frequency of follow up visits and adopt standardized approaches to blood pressure (BP) measurements and antihypertensive medication regimen advancement defined as adding or titrating existing medication. This quasi-experimental study used 2017-2019 data from 63,497 patients with hypertension and multivariable difference-in-differences analyses to evaluate changes in outcomes at 19 adopter versus 39 non-adopter sites before and after HCPP implementation. Adoption was associated with 3.5 times differentially greater odds of a BP reassessment (OR 3.5, 95% CI 3.3-3.8), 11% differentially greater odds of BP control (BP<140/90 mmHg) (OR 1.11, 95% CI 1.07-1.15), and 12% differentially greater odds of having non-severely elevated BP (systolic BP < 155 mmHg) (OR 1.12, 95% CI 1.05-1.19). HCPP adoption was not associated with differential changes in 90-day follow-up BP measurement. Adoption was associated with 23% differentially greater odds of appropriate medication advancement (OR 1.23, 95% CI 1.04-1.46). A similar pattern was observed when limiting comparisons to sites caring for a higher proportion of historically underserved populations. A multimodal population health approach to transforming hypertension care was associated with improved BP outcomes.

Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.

Patients with CKD often have uncontrolled hypertension despite polypharmacy. Pharmacogenomic drug-gene interactions (DGIs) may affect the metabolism or efficacy of antihypertensive agents. We report changes in hypertension control after providing a panel of 11 pharmacogenomic predictors of antihypertensive response. A prospective cohort with CKD and hypertension was followed to assess feasibility of pharmacogenomic testing implementation, self-reported provider utilization, and BP control. The analysis population included 382 subjects with hypertension who were genotyped for cross-sectional assessment of DGIs, and 335 subjects followed for 1 year to assess systolic BP (SBP) and diastolic BP (DBP). Most participants (58%) with uncontrolled hypertension had a DGI reducing the efficacy of one or more antihypertensive agents. Subjects with a DGI had 1.85-fold (95% CI, 1.2- to 2.8-fold) higher odds of uncontrolled hypertension, as compared with those without a DGI, adjusted for race, health system (safety-net hospital versus other locations), and advanced CKD (eGFR <30 ml/min). CYP2C9-reduced metabolism genotypes were associated with losartan response and uncontrolled hypertension (odds ratio [OR], 5.2; 95% CI, 1.9 to 14.7). CYP2D6-intermediate or -poor metabolizers had less frequent uncontrolled hypertension compared with normal metabolizers taking metoprolol or carvedilol (OR, 0.55; 95% CI, 0.3 to 0.95). In 335 subjects completing 1-year follow-up, SBP (-4.0 mm Hg; 95% CI, 1.6 to 6.5 mm Hg) and DBP (-3.3 mm Hg; 95% CI, 2.0 to 4.6 mm Hg) were improved. No significant difference in SBP or DBP change were found between individuals with and without a DGI. There is a potential role for the addition of pharmacogenomic testing to optimize antihypertensive regimens in patients with CKD.

Changes in Hypertension Control in a Community-Based Population of Older Adults, 2011-2013 to 2016-2017.

2014 hypertension guidelines raised treatment goals in older adults. The objective was to examine changes in blood pressure (BP) control (<140/90 mm Hg) from 2011-2013 to 2016-2017 among Black and white older adults with treated hypertension. Participants were 1,600 white and 650 Black adults aged 71-90 years in the Atherosclerosis Risk in Communities (ARIC) Study with treated hypertension in 2011-2013 (baseline) who had BP measured in 2016-2017 (follow-up). Predictors of changes in BP control were examined by race. BP was controlled among 75.3% of white and 65.7% of Black participants at baseline and 59.0% of white and 56.5% of Black participants at follow-up. Among those with baseline BP control, risk factors for incident uncontrolled BP included age (relative risk [RR] 1.15 per 5 years, 95% confidence interval [CI] 1.07-1.25), female sex (RR 1.36, 95% CI 1.16-1.60), and chronic kidney disease (RR 1.19, 95% CI 1.01-1.40) among white participants, and hypertension duration (RR 1.14 per 5 years, 95% CI 1.03-1.27) and diabetes (RR 1.48, 95% CI 1.15-1.91) among Black participants. Among those with uncontrolled BP at baseline, white females vs. males (RR 0.60, 95% CI 0.46-0.78) and Black participants with chronic kidney disease vs. without (RR 0.58, 95% CI 0.36-0.93) were less likely to have incident controlled BP. BP control decreased among white and Black older adults. Black individuals with diabetes or chronic kidney disease were less likely to have controlled BP at follow-up. Higher treatment goals may have contributed to these findings and unintended differences by race.

Association Between a Temporary Reduction in Access to Health Care and Long-term Changes in Hypertension Control Among Veterans After a Natural Disaster

Temporary disruptions in health care access are common, but their associations with chronic disease control remain unknown. To evaluate whether long-term changes in chronic disease control were associated with a temporary 6-month decrease in access to health care services. This cohort study examined the long-term changes in chronic disease control associated with the 6-month closure of the Manhattan facility of the Veterans Affairs (VA) New York Harbor Healthcare System after superstorm Sandy, which caused a significant disruption in health care access for veterans in the region. Electronic health records from the VA Healthcare System between October 29, 2010, and October 29, 2014, were used to identify a total of 81 544 veterans who were and were not exposed to the 6-month closure of the VA Manhattan Medical Center after superstorm Sandy. Of those, 19 207 veterans were included in the exposed cohort and 62 337 were included in the nonexposed control cohort, which included veterans who were equally exposed to the storm but who retained regular access to health care from 3 VA medical centers (Brooklyn and the Bronx in New York and New Haven in Connecticut) during and after the storm. A difference-in-differences analysis was used to assess within-patient changes in chronic disease control over time between a cohort that was exposed to decreased health care access compared with a similar cohort that was not exposed to decreased access. All analyses adjusted for individual demographic and socioeconomic characteristics, between-zip code differences, and common time trends. Data analyses were conducted between February 1, 2016, and September 30, 2019. The 6-month closure of the VA Manhattan Medical Center after superstorm Sandy on October 29, 2012. The outcomes measured were uncontrolled blood pressure (defined as mean blood pressure per patient per quarter >140/90 mm Hg), uncontrolled diabetes (defined as mean hemoglobin A1c per patient per quarter >8%), uncontrolled cholesterol (defined as mean low density lipoprotein per patient per quarter >140 mg/dL), and patient weight. Among the 81 544 veterans included in the study, the mean (SD) age was 62.1 (17.6) years, and 93.6% were men, 62.7% were white, and 31.8% were black. At the 3-month midpoint of the 6-month facility closure of the VA Manhattan Medical Center, an absolute decrease of 24.8% (95% CI, -26.5% to -23.0%; P < .001) was observed in the percentage of veterans who had any VA primary care visit per quarter compared with a baseline of 47.8% before the closure (relative decrease, 51.9%; 95% CI, -55.4% to -48.1%; P < .001). One year after the facility reopened, no differential change was observed in the percentage of patients with a primary care visit between the exposed vs nonexposed cohorts (absolute decrease, -0.1%; 95% CI, -1.5% to 1.4%; P = .94); however, patients in the exposed cohort were 25.9% more likely to have uncontrolled blood pressure than patients in the nonexposed cohort (unadjusted increase, 5.5% in the exposed cohort vs 1.3% in the nonexposed cohort; adjusted absolute increase, 5.0%; 95% CI, 3.5%-6.0%; P < .001). Two years after superstorm Sandy, patients in the exposed cohort were 10.9% more likely to experience uncontrolled blood pressure than those in the nonexposed cohort (unadjusted increase, 5.2% in the exposed cohort vs 3.5% in the nonexposed cohort; adjusted absolute increase, 2.1%; 95% CI, 0.5%-3.6%; P < .001). Compared with the nonexposed cohort, the exposed cohort also experienced a decrease in filled medication prescriptions per patient per quarter of 6.9% during the facility closure (absolute decrease, -0.7 prescriptions filled per patient per quarter; 95% CI, -0.9 to -0.5; P < .001) and of 2.2% a year after the facility reopened (absolute decrease, -0.2 prescriptions filled per patient per quarter; 95% CI, -0.4 to -0.1; P = .04). No differential changes were observed in uncontrolled diabetes, uncontrolled cholesterol, or patient weight. In this study, a temporary period of decreased access to health care services was associated with increased rates of uncontrolled hypertension, but not with increased rates of uncontrolled diabetes or hyperlipidemia, more than 1 year after the Manhattan VA facility reopened. Temporary gaps in access to health care may be associated with long-term increases in uncontrolled blood pressure among patients with hypertension.

PP.32.02] IMPROVED TREATMENT AND CONTROL OF HYPERTENSION IN SWEDISH PRIMARY CARE

Objective: To study changes in hypertension control and antihypertensive treatment in patients treated in primary care from 2001–02 to 2007–08. Design and method: The SPCCD includes extractions from computerized medical records of 74,751 hypertensive patients treated in Swedish primary care 2001–08. The main outcome measures of this retrospective analysis were blood pressures in relation to clinical characteristics, comorbidity and pharmacotherapy. Results: The mean age of women and men in 2001–02 was 69 ± 12 and 66 ± 12 years respectively. This increased to 70 ± 13 and 67 ± 12 years. In 2001–02 72% of women and 64% of men had cardiovascular (stroke, IHD, CHF, AF) and/or diabetic comorbidity while in 2007–08 this proportion was 60% and 50% respectively. Mean blood pressure (BP) was 152 ± 19/82 ± 10 mmHg in women and 150 ± 18/84 ± 10 mmHg in men in 2001–02. In 2007–08 mean BP was 143 ± 18/79 ± 10 mmHg and 142 ± 17/81 ± 11 mmHg respectively. The proportion of all patients with BP <140/90 mmHg increased from 2001–02 to 2007–08 (22% vs 41%, p < 0.001) with the gretest improvement amongst patients with comorbidities. In patients with diabetes and cardiovascular comorbidity, BP in women decreased 151 ± 21/78 ± 11 mmHg to 141 ± 19/75 ± 11 mmHg and in men from 148 ± 19/80 ± 10 mmHg to 139 ± 18/76 ± 11 mmHg and the proportion with BP <140/90 mmHg increased from 22% to 43% and from 25% to 49% respectively (all p < 0.001). Main drug classes used in 2001–02 and 2007–08 were ACEI (17% and 28%), ARB (9% and 16%), beta-blockers (48% and 41%), calcium antagonists (23% and 22%), and diuretics (34% and 42%), respectively. The mean number of drugs used to treat was 1.5 in both genders in 2001–02 and 1.7 in women and 1.8 in men in 2007–08 (p < 0.001). The mean number of drugs used to treat patients who reached BP <140/<90 mmHg was 1.5 in women and 1.6 in men in 2001–02 and 1.7 and 1.8 respectively in 2007–08 (p < 0.001). Conclusions: Blood pressure control in Swedish primary care has improved as did the use of ACEI and ARBS. However, the combination of several drug classes in patients with insufficient blood pressure control remains underused. There is room for further improvement.

Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010.

Joint National Committee goal blood pressure for all adults was <140/<90 mm Hg or lower from 1984 to 2013. Adults aged ≥60 years (older) have mainly isolated systolic hypertension, with major trials attaining systolic blood pressure <150 but not <140 mm Hg. The main objective was to assess changes in hypertension control to <140/<90 mm Hg in younger (aged <60 years) and older adults and <150/<90 mm Hg in the latter. National Health and Nutrition Examination Surveys (NHANES) 1988 to 1994, 1999 to 2004, and 2005 to 2010 were analyzed in adults aged ≥18 years. From 1988 to 1994 to 2005 to 2010, hypertension control to <140/<90 mm Hg improved in older (31.6% to 53.1%; P<0.001) and younger (45.7% to 55.9%; P<0.001) patients. The age gap in control declined from 14.1% (P<0.01) in 1988 to 1994 to 2.8% (P=0.13) in 2005 to 2010. Better hypertension control reflected increased percentages of older (55.6% to 77.5%) and younger (34.6% to 54.7%) patients on treatment and treated older (45.7% to 64.9%) and younger (56.8% to 73.4%) patients controlled (all P<0.001). Control to <150/<90 mm Hg rose from 48.8% to 69.9% in older adults. Antihypertensive medication number and percentages on ≥3 medications increased in both age groups but increased more in older patients (P<0.01). Blood pressure control was higher in both age groups with ≥2 healthcare visits per year and on statin therapy. The age gap in hypertension control to <140/<90 mm Hg was virtually eliminated in 2005 to 2010 as clinicians intensified therapy, especially in older patients in whom isolated systolic hypertension predominates, controlling 70% to <150/<90 mm Hg. More frequent healthcare visits and the use of statin therapy may improve hypertension control in all adults.

Predicting changes in hypertension control using electronic health records from a chronic disease management program

Common chronic diseases such as hypertension are costly and difficult to manage. Our ultimate goal is to use data from electronic health records to predict the risk and timing of deterioration in hypertension control. Towards this goal, this work predicts the transition points at which hypertension is brought into, as well as pushed out of, control. In a cohort of 1294 patients with hypertension enrolled in a chronic disease management program at the Vanderbilt University Medical Center, patients are modeled as an array of features derived from the clinical domain over time, which are distilled into a core set using an information gain criteria regarding their predictive performance. A model for transition point prediction was then computed using a random forest classifier. The most predictive features for transitions in hypertension control status included hypertension assessment patterns, comorbid diagnoses, procedures and medication history. The final random forest model achieved a c-statistic of 0.836 (95% CI 0.830 to 0.842) and an accuracy of 0.773 (95% CI 0.766 to 0.780). This study achieved accurate prediction of transition points of hypertension control status, an important first step in the long-term goal of developing personalized hypertension management plans.

Cost‐Effectiveness Evaluation of a Collaborative Patient Education Hypertension Intervention in Utah

This study analyzed the cost-effectiveness of a patient hypertension education intervention that provided patient education through interactive voice response technology and distribution of automated blood pressure monitors to high-risk plan members with uncontrolled hypertension. A total of 17,318 members were identified with hypertension in an administrative database. The study sample consisted of all 534 high-risk hypertensive plan members who received blood pressure monitors. Using data on activity-based program costs and changes in hypertension control, this study modeled the intervention's cost-effectiveness relative to no intervention. The intervention was estimated to have brought hypertension under control in 151 patients during the study year. Across all 534 participants in 1 year, 0.3 events (acute myocardial infarction, stroke, congestive heart failure, and renal failure) were avoided and 2.77 life-years were gained (LYG). The incremental cost-effectiveness ratio (ICER) for the intervention compared with no intervention was $767 per person brought under control or $41,927 per LYG. If the gains in hypertension control from 1 year's investment were assumed to last 10 years, the 10-year ICER relative to no intervention was $1857 per LYG. The intervention is a cost-effective strategy to address hypertension and can serve as a model for future innovations.

Control of arterial hypertension in Spain

Hypertension is a leading global risk factor for the burden of cardiovascular disease. Data about changes in hypertension control are important to set intervention priorities. We conducted a systematic review and meta-analysis of epidemiological studies to determine the control of hypertension in Spain over the past decade. A search of PubMed/MEDLINE, SCOPUS and IME was performed for epidemiological studies conducted in Spain (since 2000) with data on control rates for hypertension. The primary outcome was the prevalence of uncontrolled hypertension defined as the percentage of patients having SBP at least 140 mmHg and/or DBP at least 90 mmHg. For populations at risk (e.g. patients with diabetes), the definition was SBP at least 130 mmHg and/or DBP at least 80-85 mmHg. Seventy-six studies evaluating 341 632 patients (79% with hypertension) met the inclusion criteria. Among hypertensive patients, the overall pooled prevalence of uncontrolled hypertension (≥140/90 mmHg) was 67.0% [95% confidence interval (CI) 64.1-69.9%], but was 87.6% (95% CI 86.2-89.0%) when the most restricted definition (≥130/80-85 mmHg) was used for patients at risk. The test for heterogeneity was significant (P < 0.001). Using metaregression analyses, we showed that the prevalence of uncontrolled hypertension did not change significantly over time, but the percentage of patients receiving at least two antihypertensive drugs increased (P = 0.032 and 0.001). In Spain, the control of hypertension is far from optimum and does not appear to have improved in recent years despite the increased intensity of therapy. Patients at risk with comorbidities appear to be controlled worse.

Hypertension Risk Prediction

Hypertension has been recognized for decades as a major predictor of adverse outcomes, including stroke, heart failure, end-stage renal disease, heart disease, and peripheral vascular disease. These disease risk estimates are the key components for the development and implementation of prevention, treatment, and control guidelines with a general theme of lower blood pressure levels associated with less adverse events.1 The public health burden from high blood pressure and the process to design interventions are further complicated by the high proportion of the population affected (≈1 in 3 adults), a linear increase with age, and disproportionally higher rates for segments of the population, such as blacks and Hispanics.2 Changes in awareness, treatment, and control of hypertension can be assessed and monitored in the population with a series of cross-sectional observational studies. Although these prevalence rates can be determined from single measurements in time, hypertension management and prevention strategies are dependent on incidence rates and the disease progression. These evidence-based guidelines are dependent on incidence and progression rates of …

Effects of the Israel doctors' strike on hypertension control in Ashdod.

We examined hypertension control during the Israel doctors' strike in a defined insured population of known hypertensives enrolled in a nurse-based hypertension control program. The strike was associated with a measurable increase in the prevalence of uncontrolled hypertension which was limited to males of relatively higher social class. No strike-related changes in hypertension control were seen for women or lower social class males. We infer from this finding that the presence of a physician is a necessary component of good hypertension control in the sub-group of males of higher socioeconomic status. The incidence of hypertension-related complications in this relatively non-compliant subpopulation needs further investigation.